German non-profit organization DEBRA Research GmbH, supporting those affected by epidermolysis bullosa (EB), and Denmark’s LEO Pharma announced a non-exclusive strategic partnership.

Leo Pharma has stepped up to commercialize toripalimab in Europe, inking a deal with Shanghai Junshi Biosciences to secure ...

A class action settlement has been reached in Stewart v. LEO Pharma Inc. et al, S.C.B.C. No. S2010053 (the "Claim").

Gilead Sciences and LEO Pharma have entered a strategic collaboration to expedite the development and commercialisation of the latter’s small molecule oral signal transducer and activator of ...

Junshi Biosciences and TopAlliance are set to enter a collaboration with LEO Pharma to distribute and market toripalimab in ...

The drugmaker is paying $250 million up front to acquire preclinical small molecules from LEO Pharma. Gilead will continue development of oral formulations of these potential drugs, while ...

Jan 11 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat patients with inflammatory ...

(RTTNews) - Gilead Sciences, Inc. (GILD) and LEO Pharma entered strategic partnership to develop and commercialize LEO Pharma's small molecule oral STAT6 (signal transducer and activator of ...

DEBRA Research and LEO Pharma announce strategic partnership to enhance treatments for Epidermolysis Bullosa (EB), a rare skin disease with no approved treatment options ...